Pancreatic Cancer Research

ResearcherUtrecht UniversityActive in the last 2 years

Marieke S. Walma

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5090311004. Sources: OpenAlex.

Their work

Papers
18 (first author 6, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
59
Papers, trials and grants by year

2016: 2 papers · 2017: none · 2018: 1 paper · 2019: 3 papers · 2020: none · 2021: 5 papers · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: 2 papers · 2026: 1 paper

Papers 18

  1. Radiofrequency Ablation and Chemotherapy vs Chemotherapy Only in Locally Advanced Pancreatic Cancer: The PELICAN Randomized Clinical Trial. Co-author DOI 10.1001/jamanetworkopen.2026.3861↗
  2. Evaluation of Short and Long-term Outcomes After Resection in Patients With Locally Advanced Versus (Borderline) Resectable Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006289↗
  3. Nationwide implementation of the international multidisciplinary best-practice for locally advanced pancreatic cancer (PREOPANC-4): study protocol. Co-author DOI 10.1186/s12885-025-13554-w↗
  4. Minimum and Optimal CA19-9 Response After Two Months Induction Chemotherapy in Patients With Locally Advanced Pancreatic Cancer: A Nationwide Multicenter Study. Co-author DOI 10.1097/sla.0000000000006021↗
  5. The Difficulty of Detecting Occult Metastases in Patients with Potentially Resectable Pancreatic Cancer: Development and External Validation of a Preoperative … Co-author DOI 10.3390/jcm13061679↗
  6. Early Recurrence After Resection of Locally Advanced Pancreatic Cancer Following Induction Therapy: An International Multicenter Study. Co-author DOI 10.1097/sla.0000000000005666↗
  7. Short- and Long-Term Outcomes of Pancreatic Cancer Resection in Elderly Patients: A Nationwide Analysis. Co-author DOI 10.1245/s10434-022-11831-7↗
  8. Predicting overall survival and resection in patients with locally advanced pancreatic cancer treated with FOLFIRINOX: Development and internal validation of t… First author DOI 10.1002/jso.26567↗
  9. Treatment strategies and clinical outcomes in consecutive patients with locally advanced pancreatic cancer: A multicenter prospective cohort. Co-author DOI 10.1016/j.ejso.2020.11.137↗
  10. The treatment and survival of elderly patients with locally advanced pancreatic cancer: A post-hoc analysis of a multicenter registry. First author DOI 10.1016/j.pan.2020.11.012↗
  11. Survival Benefit Associated With Resection of Locally Advanced Pancreatic Cancer After Upfront FOLFIRINOX Versus FOLFIRINOX Only: Multicenter Propensity Score-… Co-author DOI 10.1097/sla.0000000000005120↗
  12. Radiofrequency ablation and chemotherapy versus chemotherapy alone for locally advanced pancreatic cancer (PELICAN): study protocol for a randomized controlled… First author DOI 10.1186/s13063-021-05248-y↗
  13. Safety of radiofrequency ablation in patients with locally advanced, unresectable pancreatic cancer: A phase II study. First author DOI 10.1016/j.ejso.2019.06.008↗
  14. Added value of intra-operative ultrasound to determine the resectability of locally advanced pancreatic cancer following FOLFIRINOX chemotherapy (IMAGE): a pro… First author DOI 10.1016/j.hpb.2019.02.017↗
  15. Locally Advanced Pancreatic Cancer: Work-Up, Staging, and Local Intervention Strategies. Co-author DOI 10.3390/cancers11070976↗
  16. Computed tomography findings after radiofrequency ablation in locally advanced pancreatic cancer. Co-author DOI 10.1007/s00261-018-1519-y↗
  17. Recent Advances in Pancreatic Cancer Surgery of Relevance to the Practicing Pathologist. Co-author DOI 10.1016/j.path.2016.05.002↗
  18. Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic Cancer. First author DOI 10.1245/s10434-016-5373-2↗

Closest collaborators

The 25 strongest of 59 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Izaak Quintus Molenaar · 16 shared papers, 2016–2025 · strength 1.63
  2. Hjalmar C. van Santvoort · 15 shared papers, 2016–2025 · strength 1.57
  3. Marc G. Besselink · 15 shared papers, 2016–2025 · strength 1.54
  4. Ignace H. J. T. de Hingh · 12 shared papers, 2019–2025 · strength 1.35
  5. Martijn W.J. Stommel · 10 shared papers, 2021–2025 · strength 1.19
  6. Vincent Erwin de Meijer · 9 shared papers, 2021–2025 · strength 1.06
  7. Sebastiaan Festen · 9 shared papers, 2021–2025 · strength 1.06
  8. Lilly J. H. Brada · 9 shared papers, 2019–2025 · strength 1.01
  9. Gijs A. Patijn · 8 shared papers, 2021–2025 · strength 0.93
  10. Lois A. Daamen · 6 shared papers, 2021–2025 · strength 0.79
  11. Bas Groot Koerkamp · 6 shared papers, 2019–2024 · strength 0.71
  12. Nadia Haj Mohammad · 7 shared papers, 2016–2024 · strength 0.63
  13. Johanna W. Wilmink · 7 shared papers, 2016–2024 · strength 0.61
  14. Casper H.J. van Eijck · 5 shared papers, 2016–2024 · strength 0.51
  15. Krijn P. van Lienden · 6 shared papers, 2019–2021 · strength 0.50
  16. Leonard W. F. Seelen · 3 shared papers, 2023–2025 · strength 0.49
  17. Maarten Simon van Leeuwen · 5 shared papers, 2018–2021 · strength 0.41
  18. Thijs J. Schouten · 3 shared papers, 2021–2025 · strength 0.40
  19. Steffi J. E. Rombouts · 5 shared papers, 2016–2021 · strength 0.36
  20. Martijn Ruben Meijerink · 4 shared papers, 2019–2021 · strength 0.33
  21. Freek D. Daams · 3 shared papers, 2021–2024 · strength 0.31
  22. Vincent P. Groot · 2 shared papers, 2023–2024 · strength 0.28
  23. Vincent B. Nieuwenhuijs · 2 shared papers, 2022–2024 · strength 0.26
  24. Bert A. Bonsing · 2 shared papers, 2022–2024 · strength 0.26
  25. Geert Kazemier M · 2 shared papers, 2022–2024 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.